You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美國斥近20億美元購買輝瑞及BioNTech新冠疫苗
阿思達克 07-23 11:10
美國政府斥19.5億美元購買輝瑞(Pfizer)與德國生物科技公司BioNTech研發的1億劑新冠病毒疫苗,受消息帶動,復星醫藥(02196.HK)現升5.5%至36.45元,最高見37.3元近兩年高。BioNTech是復星醫藥的戰略合作伙伴。

根據美國與輝瑞及BioNTech的協議,美國政府可以有權購買額外5億劑疫苗,而費用將另外商議。輝瑞發言人稱,除非疫苗在大規模臨床試驗中取得成功並能夠順利生產,否則將不會收取美國政府任何資金。

輝瑞稱,希望最快下周就能展開疫苗後期階段試驗,目前有待監管當局批准,集團目標在今年底於全球生產1億劑疫苗,到明年底產量可能超過13億劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account